A federal court issued a preliminary injunction against Dr. Reddy’s generics for Indivior’s addiction treatment Suboxone (buprenorphine and naloxone) pending the outcome of a patent challenge.

Indivior filed a patent infringement complaint against Dr. Reddy’s in February, also naming Teva, Par Utah and Mylan. In late June, the U.S. District Court for the District of New Jersey granted a temporary restraining order against Dr. Reddy’s.

Prior to the restraining order, Dr. Reddy’s had opted to launch the generic “at-risk,” continuing to produce it under the assumption that it would prevail in the case. If Dr. Reddy’s wins, Indivior will be liable for $18 million in sales lost while the restraining order was in effect.